MK0683 Phase1 Clinical Study - Solid Tumor -
Phase 1
20 Years
N/A
20 Years
N/A
Not Enrolling
Both
Tumors
Both
Tumors
Trial Information
MK0683 Phase1 Clinical Study - Solid Tumor -
Inclusion Criteria:
- Patients with histologically or cytologically diagnosed solid tumor in whom no
standard therapy is available or the malignancy is refractory to standard therapy
Exclusion Criteria:
- Patients with history of immunotherapy, radiotherapy, surgery, or chemotherapy during
the previous 4 weeks
- Any uncontrolled concomitant illness
- Pregnant or breast-feeding
- Serious drug or food allergy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Number of Participants With a Dose Limiting Toxicity (DLT)
Outcome Time Frame:
21 Days (first cycle)
Safety Issue:
Yes
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Merck
Authority:
Japan: Pharmaceuticals and Medical Devices Agency
Study ID:
2006_030
NCT ID:
NCT00373490
Start Date:
July 2006
Completion Date:
July 2008
Related Keywords:
- Tumors
Name | Location |
|---|
